DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Navelbine (Drug); Capecitabine (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Craig A. Bunnell, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute

Summary

The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine given with oral navelbine to patients with advanced breast cancer.

Clinical Details

Official title: A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To define the maximally tolerated dose and evaluate the feasibility and toxicity of capecitabine and oral navelbine administered in combination.

Detailed description:

- Not every patient will be receiving the same dose of capecitabine and navelbine. A

small group will be enrolled onto the study and given certain doses of each drug. If they tolerate them well (have few or easily manageable side effects), the next small group of people enrolled will receive a higher dose of one of the drugs. This will continue until we find the highest doses of the drugs that can be given without causing serious or unmanageable side effects.

- Patients will be given oral navelbine on days 1 and 8 of each cycle, unless they are at

the highest dose. In which case, they will be given navelbine on days 1, 8 and 15. Capecitabine will be given on days 1-14 of each cycle in two divided doses approximately 12 hours apart.

- While patients are on the study they will have the following tests and procedures

performed: physical examination every 3 weeks; routine blood work every week; extensive laboratory tests every 3 weeks; disease status will be checked every 6 weeks (2 cycles) unless there are symptoms of disease progression.

- The weekly treatment will continue unless there is disease progression or unacceptable

side effects.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Histologically confirmed breast cancer with evidence of locally advanced or

metastatic disease

- Female patients age 18 or older

- No more than three prior chemotherapeutic regimens in the metastatic setting

- ANC > 1,500/mm3

- Platelet count > 100,000/mm3

- SGOT < 3 x ULN

- Bilirubin < 1. 5 x ULN

- Performance status of 0 or 1

- At least 3 weeks since prior chemotherapy or 2 weeks since prior radiation, surgery

or any anticancer investigational agent

- Able to swallow and retain oral medications

- Measurable disease

Exclusion Criteria:

- Prior vinca alkaloids

- Active gastrointestinal disease or disorder

- Pregnant or lactating

- Serious co-morbid medical or psychological condition

- Prior bone marrow or stem cell transplant

- Prior documented severe sensitivity to 5-FU

Locations and Contacts

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Massachusetts General Hospital, Boston, Massachusetts 02114, United States

Additional Information

Starting date: March 2002
Last updated: February 5, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017